OL
The startup has developed a dynamic pharmacokinetic model specifically for retinal diseases, which optimizes dose selection and frequency while comparing drug activity and duration against existing products. This approach minimizes risks and costs associated with preclinical and clinical studies, enabling pharmaceutical companies to efficiently refine retinal drug formulations.
Updated 3 months ago
Funding
$480K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup has developed a dynamic pharmacokinetic model specifically for retinal diseases, which optimizes dose selection and frequency while comparing drug activity and duration against existing products. This approach minimizes risks and costs associated with preclinical and clinical studies, enabling pharmaceutical companies to efficiently refine retinal drug formulations.